Brief: Captor Therapeutics Updates On Developments In CT-03 Project

Captor Therapeutics SA

28/09/2021 07:10

Sept 28 (Reuters) - Captor Therapeutics SA  CTXP.WA :
    * UPDATES ON RESEARCH AND DEVELOPMENT DEVELOPMENTS IN THEIR
CT-03
PROJECT
    * COMPANY'S ANALYSIS SHOWS SMALL-MOLECULE COMPOUNDS
DEVELOPED
UNDER PROJECT EFFICIENTLY DEGRADE MCL-1 PROTEIN
    * DEGREDATION ACTIVITY OF COMPOUNDS WAS DEMOSTRATED IN
WIDE-RANGE
OF CANCER MODELS
    * MCL-1 PROTEIN IS MOLECULAR TARGET OF CT-03 PROJECT
    * MCL-1 IS MAIN FACTOR EFFECTING SURVIVABILITY IN MANY TYPES
OF
CANCER, MAKING ITS TARGETED DEGRADATION ATTRACTIVE TREATMENT

Source text for Eikon:  ID:nEM68PrRka 
Further company coverage:  CTXP.WA 

 (Reporting by Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))